Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy

Cancer Cell. 2009 Jan 6;15(1):3-5. doi: 10.1016/j.ccr.2008.12.011.

Abstract

While targeting VEGF has shown success against a number of human cancers, drug resistance has resulted in compromised clinical benefits. In this issue of Cancer Cell, Crawford et al. (2009) report that tumors resistant to anti-VEGF therapy stimulate tumor-associated fibroblasts to express proangiogenic PDGF-C, implicating it as a potential therapeutic target.

Publication types

  • Comment

MeSH terms

  • Antibodies / immunology
  • Antibodies / therapeutic use*
  • Drug Resistance, Neoplasm* / drug effects
  • Fibroblasts / metabolism*
  • Fibroblasts / pathology
  • Humans
  • Immunotherapy
  • Lymphokines / metabolism
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neoplasms / immunology*
  • Neoplasms / metabolism
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / immunology
  • Neovascularization, Pathologic / metabolism
  • Platelet-Derived Growth Factor / metabolism
  • Vascular Endothelial Growth Factor A / immunology*

Substances

  • Antibodies
  • Lymphokines
  • Platelet-Derived Growth Factor
  • Vascular Endothelial Growth Factor A
  • platelet-derived growth factor C